IMblaze370試験、主要評価項目を達成せず:ESMO World GI Congress 2018【ESMO】

MSS/MSI-Lの進行大腸がんへの抗PD-1抗体アテゾリズマブ+MEK阻害薬cobimetinib


ESMO World GI Congress 2018: IMblaze370 study Did Not Meet Its Primary Endpoint
Studying combination of atezolizumab with cobimetinib in patients with MSS/MSI-L metastatic CRC

 

 

 

コメント

Leave a comment

Your email address will not be published.


*